235 related articles for article (PubMed ID: 25304423)
1. [Morphological diagnostics of malignant pleural mesothelioma].
Junker K; Müller KM
Pathologe; 2014 Nov; 35(6):586-90. PubMed ID: 25304423
[TBL] [Abstract][Full Text] [Related]
2. [Pathology of primary tumours of the pleura].
Junker K; Krismann M
Zentralbl Chir; 2008 Jun; 133(3):222-6. PubMed ID: 18563685
[TBL] [Abstract][Full Text] [Related]
3. Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
Nind NR; Attanoos RL; Gibbs AR
Histopathology; 2003 Feb; 42(2):150-5. PubMed ID: 12558747
[TBL] [Abstract][Full Text] [Related]
4. [A new one in the lung and pleura neoplasms classification (WHO, 2021, 5th edition)].
Belkin AN; Freynd GG
Arkh Patol; 2022; 84(5):28-34. PubMed ID: 36178219
[TBL] [Abstract][Full Text] [Related]
5. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
6. [Pleural mesothelioma. Cytology and molecular diagnostics].
Vlajnic T; Savic S; Bubendorf L
Pathologe; 2014 Nov; 35(6):591-6. PubMed ID: 25069847
[TBL] [Abstract][Full Text] [Related]
7. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
Cagle PT; Churg A
Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
[TBL] [Abstract][Full Text] [Related]
8. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
9. Benign pleural lesion and malignant mesothelioma.
Klima M; Gyorkey F
Virchows Arch A Pathol Anat Histol; 1977 Nov; 376(3):181-93. PubMed ID: 145715
[TBL] [Abstract][Full Text] [Related]
10. Pathohistological diagnosis and differential diagnosis.
Tischoff I; Neid M; Neumann V; Tannapfel A
Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
[TBL] [Abstract][Full Text] [Related]
11. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
12. [Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
Krismann M; Thattamparambil P; Simon F; Johnen G
Pathologe; 2006 Mar; 27(2):99-105. PubMed ID: 16435096
[TBL] [Abstract][Full Text] [Related]
13. β-catenin expression in benign and malignant pleural disorders.
Anani W; Bruggeman R; Zander DS
Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
[TBL] [Abstract][Full Text] [Related]
14. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Galateau-Salle F; Churg A; Roggli V; Travis WD;
J Thorac Oncol; 2016 Feb; 11(2):142-54. PubMed ID: 26811225
[TBL] [Abstract][Full Text] [Related]
15. Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value.
Shaker N; Wu D; Abid AM
Diagn Cytopathol; 2022 Nov; 50(11):532-537. PubMed ID: 36069384
[TBL] [Abstract][Full Text] [Related]
16. Pathology of mesothelioma.
Corson JM
Thorac Surg Clin; 2004 Nov; 14(4):447-60. PubMed ID: 15559051
[TBL] [Abstract][Full Text] [Related]
17. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
18. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
[TBL] [Abstract][Full Text] [Related]
19. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
20. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
Müller AM; Franke FE; Müller KM
Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]